Merck & Co. Newsletter
-
Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & Co., Novo Nordisk, Eli Lilly and Company, Biocon
23 Apr 2024 17:00 GMT
New York, USA, April 23, 2024 (GLOBE NEWSWIRE) -- Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & Co., …
-
Merck’s net income for Q1 2024 increases by 69% to $4.76bn
26 Apr 2024 12:07 GMT
Merck & Co Inc (MSD) has reported a significant increase in net income attributable to shareholders, reaching $4.76bn in the first quarter (Q1) of 2024, a 69% rise from $2.82bn in the first quarter of the previous year.
This financial performance …
-
Drug Delivery Technologies market is projected to grow at a CAGR of 5.5% by 2034: Visiongain
26 Apr 2024 13:14 GMT
Visiongain has published a new report entitled Drug Delivery Technologies Market Report 2024-2034: Forecasts by Route of Administration (Implantable Drug Delivery, Injectable Drug Delivery Nasal Drug Delivery, Ocular Drug Delivery, Oral Drug Delivery, …
-
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
26 Apr 2024 07:13 GMT
The CNN Money Fear and Greed index showed a slight improvement in the overall market sentiment, while the index remained in the “Fear” zone on Thursday.
U.S. stocks settled lower on Thursday, following the release of economic reports.
The U.S. economy grew …
-
Novo Nordisk lands back in Sanders' crosshairs, this time over steep costs of Ozempic and Wegovy
26 Apr 2024 01:26 GMT
Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co., and Johnson & Johnson about the high costs of their drugs, Sen. Bernie Sanders, I-Vermont, is taking Novo Nordisk to task for allegedly turning its blockbuster GLP-1s, …
-
US close: Rising yields hit stocks as inflation proves sticky in Q1
26 Apr 2024 00:05 GMT
Despite paring losses by the close, the Dow still finished down 0.98%, while the S&P 500 fell 0.46% and the Nasdaq dropped 0.64%, as investors continued to digest a barrage of corporate earnings from some heavyweight names.
US GDP growth slowed by more …
-
Markets today: Wall Street roiled as data crush Fed-pivot hopes
25 Apr 2024 20:59 GMT
Wall Street was rattled by data that showed exactly what investors did not want to hear: a sharp slowdown in the world’s largest economy and stubborn inflationary pressures.
Treasuries sold off, with yields hitting fresh 2024 highs as the economic figures …
-
Merck (MRK) Q1 2024 Earnings Call Transcript
25 Apr 2024 20:15 GMT
MRK earnings call for the period ending March 31, 2024.
Image source: The Motley Fool.
Merck (MRK 2.83%)
Q1 2024 Earnings Call
Apr 25, 2024, 9:00 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:
Operator
Thank …
-
Gilead Sciences Announces First Quarter 2024 Financial Results
25 Apr 2024 20:12 GMT
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.
“Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology …
-
US open: Stocks sharply lower following macro data, tech earnings
25 Apr 2024 19:16 GMT
As of 1530 BST, the Dow Jones Industrial Average was down 1.67% at 37,816.94, while the S&P 500 lost 1.32% to 5,004.57 and the Nasdaq Composite came out the gate 1.64% weaker at 15,455.24.
The Dow opened 643.98 points lower on Thursday, extending …